文献速递乳腺癌

FCGR2A与FCGR3A基因多态性与ERBB2/HER2阳性乳腺癌辅助治疗中曲妥珠单抗获益程度的关联:NSABP B-31试验分析

Association of Polymorphisms in FCGR2A and FCGR3A With Degree of Trastuzumab Benefit in the Adjuvant Treatment of ERBB2/HER2-Positive Breast Cancer: Analysis of the NSABP B-31 Trial.
PubMed 文献 · JAMA Oncol · 2017-01-01

该研究为NSABP B-31试验的回顾性分析,纳入1251例基因分型患者,评估FCGR2A和FCGR3A多态性对曲妥珠单抗辅助治疗疗效的影响。中位随访8.2年,曲妥珠单抗显著改善无病生存(HR 0.46,95%CI 0.37-0.57,P<.001)。仅FCGR3A-158多态性与曲妥珠单抗交互作用达统计学显著(P<.001),FCGR3A-158V/V或V/F基因型患者获益更大(HR 0.31,95%CI 0.22-0.43,P<.001),而低亲和力等位基因纯合子获益较小(HR 0.71,95%CI 0.51-1.01,P=.05)。

要点

  • FCGR3A-158多态性与曲妥珠单抗疗效存在显著交互作用(P<.001)。
  • FCGR3A-158V/V或V/F基因型患者从曲妥珠单抗获益更大(HR 0.31)。
  • 低亲和力等位基因纯合子患者曲妥珠单抗获益较小(HR 0.71,95%CI 0.51-1.01)。

核心结论

  • FCGR3A-158多态性可预测该早期ERBB2/HER2阳性乳腺癌队列中曲妥珠单抗的疗效。
  • 该位点苯丙氨酸纯合子患者占人群相当比例,与既往同类设计试验分析不同,本研究结果提示曲妥珠单抗在这类患者中可能疗效较低。

研究设计与样本

  • 本研究为对NSABP B-31试验入组患者的回顾性分析,该试验为2000年至2005年间开展的3期协作组研究。
  • NSABP B-31试验随机分配2119例手术切除后淋巴结阳性、ERBB2/HER2阳性乳腺癌女性,接受多柔比星和环磷酰胺后序贯紫杉醇,或相同方案加1年每周曲妥珠单抗。
  • 患者来自美国和加拿大的协作组站点,本分析于2013年至2016年间进行。
  • 基因分型队列N=1251,其临床变量和曲妥珠单抗获益程度与整个B-31队列相似。
  • 基因分型样本中位随访时间为8.2年。

主要发现

  • 接受ACT方案患者3年、5年和8年无病生存概率分别为74%(95%CI 71%-79%)、66%(95%CI 62%-71%)和58%(95%CI 54%-63%)。
  • 接受ACTH方案患者3年、5年和8年无病生存概率分别为86%(95%CI 83%-89%)、82%(95%CI 79%-85%)和78%(95%CI 74%-81%)。
  • 加用曲妥珠单抗显著改善患者结局(HR 0.46,95%CI 0.37-0.57,P<.001)。
  • 两种基因的多态性与曲妥珠单抗交互作用均呈现预期趋势,但仅FCGR3A-158多态性交互作用达统计学显著(P<.001)。
  • FCGR3A-158V/V或V/F基因型患者从曲妥珠单抗获益更大(HR 0.31,95%CI 0.22-0.43,P<.001),而低亲和力等位基因纯合子患者获益较小(HR 0.71,95%CI 0.51-1.01,P=.05)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Preclinical models and studies in the metastatic and neoadjuvant settings suggest that single nucleotide polymorphisms in FCGR3A and FCGR2A may be associated with differential response to trastuzumab in the treatment of ERBB2/HER2-positive breast cancer, by modulating antibody-dependent cell-mediated cytotoxic effects. OBJECTIVE: To evaluate the effect of FCGR2A and FCGR3A polymorphisms on trastuzumab efficacy in the adjuvant treatment of ERBB2/HER2-positive breast cancer. DESIGN, SETTING, AND PARTICIPANTS: This is a retrospective analysis of patients enrolled in the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-31 trial, a phase 3 cooperative group study conducted between 2000 and 2005. The NSABP B-31 trial randomized 2119 women with surgically resected node-positive, ERBB2/HER2-positive breast cancer to treatment with doxorubicin and cyclophosphamide followed by paclitaxel or the same regimen with the addition of 1 year of weekly trastuzumab. Patients were accrued at cooperative group sites across the United States and Canada. This analysis was performed between 2013 and 2016. INTERVENTIONS: Doxorubicin and cyclophosphamide followed by paclitaxel or the same regimen with the addition of 1 year of weekly trastuzumab. MAIN OUTCOMES AND MEASURES: Disease-free survival. RESULTS: The genotyped cohort (N = 1251) resembled the entire B-31 cohort based on clinical variables and the degree of benefit from trastuzumab. Median follow-up time was 8.2 years in the genotyped samples. The disease-free survival probability at 3, 5, and 8 years was 74% (95% CI, 71%-79%), 66% (95% CI, 62%-71%), and 58% (95% CI, 54%-63%) in patients who received ACT and 86% (95% CI, 83%-89%), 82% (95% CI, 79%-85%), and 78% (95% CI, 74%-81%) in patients who received ACTH. Addition of trastuzumab significantly improved patient outcome (hazard ratio [HR], 0.46; 95% CI, 0.37-0.57; P < .001). The expected trend for interaction between polymorphisms and trastuzumab was observed for both genes, but only FCGR3A-158 polymorphism reached statistical significance for interaction (P < .001). As hypothesized, patients with genotypes FCB3A-158V/V or FCB3A-158V/F received greater benefit from trastuzumab (HR, 0.31; 95% CI, 0.22-0.43; P < .001) than patients who were homozygous for the low-affinity allele (HR, 0.71; 95% CI, 0.51-1.01; P = .05). CONCLUSIONS AND RELEVANCE: The FCGR3A-158 polymorphism is predictive of trastuzumab efficacy in this cohort of patients with early ERBB2/HER2-positive breast cancer. Patients who are homozygous for phenylalanine at this position represent a considerable proportion of the population and, in contrast to previously reported analyses from similarly designed trials, our results indicate that trastuzumab may be less efficacious in these patients. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00004067.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Gavin PG, Song N, Kim SR, et al. Association of Polymorphisms in FCGR2A and FCGR3A With Degree of Trastuzumab Benefit in the Adjuvant Treatment of ERBB2/HER2-Positive Breast Cancer: Analysis of the NSABP B-31 Trial. JAMA Oncol. 2017. PMID: 27812689. doi:10.1001/jamaoncol.2016.4884

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。